# 2026-05486: DEA Lists New Chemical Mixes Free from Drug Control Hassles

2026-05486, Exempt Chemical Preparations Under the Controlled Substances Act, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-03-20, effective Comments must be submitted electronically or postmarked on or before May 19, 2026.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-05486
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05486
- Title: Exempt Chemical Preparations Under the Controlled Substances Act
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 13610
- Published: 2026-03-20
- Effective: Comments must be submitted electronically or postmarked on or before May 19, 2026.
- Comments close: 2026-05-19
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

DEA Lists New Chemical Mixes Free from Drug Control Hassles

## Summary

The Drug Enforcement Administration (DEA) just updated which chemical mixes are officially exempt from strict drug rules between September 2024 and December 2025. Companies and labs using these chemicals should check the new list to see if their products are approved or denied. You’ve got until May 19, 2026, to share your thoughts, and no extra fees are involved—just a quick review and comment if you want!

## Abstract

The applications for exempt chemical preparations received by the Drug Enforcement Administration between September 1, 2024, and December 31, 2025, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through December 31, 2025, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.

## Effects PRIA read

- Listed preparations exempted from select CSA rules: benefit, medium. The DEA accepted applications filed between September 1, 2024 and December 31, 2025 and determined that the specific preparations listed in Chart I are exempt, to the extent described in 21 CFR 1308.24, from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 of the Cont…
- Bulk exempt products restricted to in-house use: cost, medium. For exempted bulk products, DEA determined they may only be used in-house by the manufacturer and may not be distributed for any purpose or transported to other facilities. This restriction is intended to limit diversion opportunities for larger bulk quantities.
- Changes to prep or name require new application: cost, low. DEA states that any change in the quantitative or qualitative composition of an exempt preparation, or a change in the trade name or other designation after the application date, requires a new application under 21 CFR 1308.24(h).
- Exemption does not remove other CSA/CFR duties: cost, low. DEA notes that the exemptions are limited to specific sections identified in 21 CFR 1308.24(a) and that all other requirements of the CSA and CFR still apply, including registration as an importer required by 21 U.S.C. 957.
- Opportunity to comment by May 19, 2026: benefit, low. Interested persons may submit comments on this order electronically or by mail; comments must be submitted or postmarked on or before May 19, 2026. DEA encourages electronic submissions via Regulations.gov (reference Docket No. DEA-372).

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-05486 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/20/2026-05486/exempt-chemical-preparations-under-the-controlled-substances-act)
- [2026-05486 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-20/pdf/2026-05486.pdf)

## Related
- [Previous: 2026-05485, CSX Transportation, Inc.-Discontinuance Exemption-in Cook County, Ill](https://policyrisk.com/federal-register/2026-05485)
- [Next: 2026-05487, Fermi America LLC (dba Fermi America); Project Matador Advanced Energy and Inte…](https://policyrisk.com/federal-register/2026-05487)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05486 (as of 2026-06-08).
